# A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors

> **NCT02223247** · PHASE1 · COMPLETED · sponsor: **Sagimet Biosciences Inc.** · enrollment: 180 (estimated)

## Conditions studied

- Solid Malignant Tumor

## Interventions

- **DRUG:** TVB-2640

## Key facts

- **NCT ID:** NCT02223247
- **Lead sponsor:** Sagimet Biosciences Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11
- **Primary completion:** 2017-06
- **Final completion:** 2017-06
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2017-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02223247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02223247, "A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02223247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*